TTK Healthcare Limited Annual Report 2025-26 Comprehensive Summary
Financial Performance Highlights
TTK Healthcare reported mixed FY26 results with revenue growth of 7% to ₹857.28 crores (PY: ₹801.49 crores) but net profit declined 20% to ₹65.68 crores (PY: ₹81.66 crores). The decline was primarily due to exceptional items including a ₹7.58 crore charge for Labour Code implementation (provision for gratuity and leave salary under New Wage Code) and a ₹3.50 crore GST refund income. Earnings per share stood at ₹46.48 compared to ₹57.79 in the previous year.
Operational Performance by Division
The company demonstrated varied performance across its business segments:
- Consumer Products Division: Revenue declined 1.5% to ₹241.28 crores (excluding Skore)
- Animal Welfare Division: Strong 12% growth to ₹141.08 crores
- Medical Devices - Heart Valve Division: Modest 2% growth to ₹29.81 crores, affected by supply constraints from Russia-Ukraine conflict
- Medical Devices - Ortho Division: Impressive 27% growth to ₹77 crores
- Protective Devices Division: 5% growth to ₹216.50 crores (including Skore), recovering from USAID business loss
- Foods Division: 14% growth to ₹150.36 crores with four new products commercialized
Corporate Actions & Governance
The Board recommended a final dividend of ₹10 (100%) per equity share, with record date fixed as July 17, 2026. Special resolutions include reappointment of Mr T T Raghunathan as Executive Chairman for five years from November 1, 2026, with remuneration equivalent to 5% of profits. Mr K Shankaran retires by rotation and seeks reappointment. The 68th Annual General Meeting is scheduled for July 24, 2026 through video conferencing.
Financial Position & Capital Structure
The company maintained a strong balance sheet with net current assets of ₹1,03,356.96 lakhs and debt-equity ratio of 0.02. Total assets stood at ₹1,14,441.18 lakhs with investments of ₹865.56 lakhs. Share capital remained unchanged at ₹1,413.03 lakhs with promoter holding at 74.56%. Capital expenditure for the year was ₹3.90 crores with estimated FY27 capex of ₹20 crores.
Regulatory Compliance & Audit Matters
The disclosure was made under Regulation 34(1) of SEBI (LODR) Regulations, 2015. Auditors provided unmodified opinions with key audit focus on revenue recognition under Ind AS 115, particularly estimating returns, discounts, and promotional expenditures. The company maintained adequate internal financial controls with no material weaknesses identified. All directors affirmed compliance with the Code of Conduct, and none were disqualified as per certification.
Key Management Remuneration
Key managerial personnel compensation included:
- T T Raghunathan: ₹455.00 lakhs
- S Kalyanaraman: ₹331.81 lakhs
- B V K Durga Prasad: ₹158.65 lakhs
- Gowry A Jaishankar: ₹27.71 lakhs
Forward Outlook & Risk Factors
The company faces challenges from geopolitical instability affecting supply chains, competitive pressures in consumer products, dependence on institutional business, and input cost volatility. Focus areas include innovation, distribution expansion, cost optimization, and sustainability initiatives. Employee strength reduced to 1,478 from 1,508, with the company receiving "Great Place to Work" certification for the third consecutive year.